NCT01502072View on ClinicalTrials.gov

Respiratory Syncytial Virus - RSV Protocol

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 28, 2011

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions
Bone Marrow Transplant InfectionInfection in Marrow Transplant RecipientsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus PneumoniaCancerAcute Leukemia
Interventions
DRUG

Ribavirin

Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.

DRUG

Ribavirin

One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01502072 - Respiratory Syncytial Virus - RSV Protocol | Biotech Hunter | Biotech Hunter